Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mirexus is a Canadian biotechnology company that has developed a unique, plant-based nanotechnology platform based on PhytoSpherix, a monodisperse phytoglycogen nanoparticle. Extracted from non-GMO sweet corn, these highly branched glucose polymers are non-toxic, biodegradable, and possess exceptional water-retention and film-forming properties. The company targets three primary markets: personal care, where PhytoSpherix is used as a high-performance moisturizing and anti-aging ingredient; nutraceuticals; and biomedical applications, including drug delivery and vaccine adjuvants. In September 2022, Mirexus was acquired by BASF, the world's largest chemical producer, to bolster its portfolio of sustainable and bio-based ingredients for the Care Chemicals division. The acquisition allows for the global scaling of the PhytoSpherix technology across various industrial and healthcare sectors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mirexus.